Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18743818 | 0.80 | MAPT (0.38) | ANPEPMAPTHDAC2ALDH1A1POLB | |
| SCHEMBL22580829 | 0.80 | MAPT (0.31) | MAPTHDAC2ALDH1A1 | |
| SCHEMBL8248045 | 0.78 | ALDH1A1 (0.38) | MAPTHDAC2ALDH1A1POLBNPC1 | |
| SCHEMBL18716626 | 0.78 | GAA (0.39) | MAPTHDAC2ALDH1A1POLBNPC1 | |
| SCHEMBL25159888 | 0.78 | ANPEP (0.35) | ANPEPRNPEPDNPEPALDH1A1NPC1 | |
| SCHEMBL20035021 | 0.77 | ANPEP (0.43) | ANPEPRNPEPDNPEPMAPTALDH1A1 | |
| SCHEMBL24927033 | 0.76 | DPP4 (0.44) | MAPTHDAC2ALDH1A1POLBNPC1 | |
| SCHEMBL18743854 | 0.76 | POLB (0.37) | MAPTHDAC2ALDH1A1POLBNPC1 | |
| SCHEMBL20035022 | 0.76 | LMNA (0.46) | ANPEPRNPEPDNPEPMAPTALDH1A1 | |
| SCHEMBL17771181 | 0.75 | CA1 (0.44) | MAPTHDAC2ALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | ANPEP 1227/4885RNPEP 1247/4885DNPEP 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.